EP-51216 is a growth hormone agonist peptide. EP-51216 increases food intake. EP-51216 can be used in the research of eating disorders.

5-Benzyloxytryptamine (5-BT) is a selective partial agonist for 5-hydroxytryptamine 1D/1B (5-HT1D/1B) receptors with an IC50 value of 40 nM for bovine caudate 5-HT1D and reduced affinity for other receptors (5-HT2 IC50>470 nM). 5-Benzyloxytryptamine inhibits adenylate cyclase to decrease neurotransmitter release and downregulate cAMP signaling. 5-Benzyloxytryptamine is promising for research of neurotransmitter imbalance-related disorders like migraine.

L694247 (TFA) is a selective 5-HT1D agonist with pIC50 values of 10.03, 8.64, 6.42, and 5.66 for 5-HT1D, 5-HT1A, 5-HT1C, and 5-HT1E receptors, respectively.

ZH8659 hydrochloride is a trace amine-associated receptor 1 (TAAR1)-Gq agonist. ZH8659 hydrochloride can be used for the research of neurological disorders.

(1-(7-Bromoheptyl)piperidin-4-yl)methanamine is a PROTAC linker. (1-(7-Bromoheptyl)piperidin-4-yl)methanamine can be used in synthesis ZS3-046.

E3 Ligase Ligand-linker Conjugate 210 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 210 can be used to synthesize PROTAC CB1R Degrader-1.

2-[4-(Aminomethyl)triazol-1-yl]ethanamine is a PROTAC Linker. 2-[4-(Aminomethyl)triazol-1-yl]ethanamine can be used to synthesize PROTAC CB1R Degrader-1.

Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM. Refinicopan inhibits rabbit erythrocyte hemolysis with an IC50 of 41 nM. Refinicopan exhibits excellent pharmacokinetic and pharmacodynamic activity.

JNJ-27390467 is a potent, orally active, and selective tryptase inhibitor (human β-tryptase IC50 = 3.6 nM, Ki = 3.7 nM). JNJ-27390467 exhibits excellent selectivity over trypsin of ~5000-fold. JNJ-27390467 shows effects in animal models of airway inflammation. JNJ-27390467 can be used for allergic asthma research.

YL6113 is a potent and selective dual inhibitor of metallo-β-lactamases (MBLs) and serine-β-lactamases (SBLs). YL6113 shows inhibitory effect to MBLs, such as NDm-1, VIM-2, IMP-1, with IC50 values of 0.25, 27.16 and 3.55 μM. YL6113 shows inhibitory effect to SBLs, such as KPC-2, AmpC, OXA-48, with IC50 values of 0.2, 34.1 and 1.31 μM. YL6113 enhances the antibacterial efficacy of Meropenem against carbapenem-resistant Gram-negative bacteria. YL6113 can be used for the research of infection.

7-MAD-MDCPT TFA, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs).

7-MAD-MDCPT hydrochloride, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs).

ER ligand-11 is the ligand for ERα and can be used for synthesis of PROTACs, such as PROTAC ERα Degrader-12.

CEB-1604 is an NMDA receptor antagonist. CEB-1604 inhibits NMDA-induced currents in oocytes transfected with NMDA receptor isoforms (NR1/NR2A, NR1/NR2B, NR1/NR2C, NR1/NR2D) with IC50 values ranging from 5 to 12 μM. CEB-1604 abolishes NMDA-dependent epileptiform discharges in rat cortical wedge preparations and reduces the depolarizing effects of NMDA. CEB-1604 can be used in the research field of neurological damage diseases.

Gly-7-MAD-MDCPT (Compound 4b) TFA is an anticancer agent. Gly-7-MAD-MDCPT TFA is a Camptothecin compound, which shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM.

Gly-7-MAD-MDCPT (Compound 4b) hydrochloride is an anticancer agent. Gly-7-MAD-MDCPT hydrochloride is a Camptothecin compound, which shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM.

Gly-Gly-Gly-PEG3-TCO TFA is a 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

BTR2000-Gly-Gly-Gly TFA is a E3 ligase ligand-linker conjugate (KLHL20) that can be used for the synthesis of PROTAC BTR2004.

(R,S,S)-VH032-Me-glycine is an E3 ligase ligand-linker conjugate. (R,S,S)-VH032-Me-glycine can be used to synthesize XF067-68.

M2 ion channel blocker-2 (Compound 10) is a M2 channel blocker. M2 ion channel blocker-2 significantly blocks wild-type and mutant M2 (L27F and V27A) ion channels. M2 ion channel blocker-2 has potent antiviral activity against HCoV-229E (EC50: 4.7  μM in cytopathic effect) but not against influenza A virus. M2 ion channel blocker-2 has no significant inhibition of hERG and cytochrome P450 (CYP1A2, CYP2C19, and CYP3A4) activity.

SMU-L11-R is a selective TLR7 agonist with an EC50 of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits  MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8+T cells. SMU-L11-R shows potential in colorectal cancer studies.

ddATP (lithium) (2',3'-Dideoxyadenosine 5'-triphosphate (lithium)) is an active metabolite of 2',3'-dideoxyinosine and a DNA polymerase chain elongation inhibitor. ddATP (lithium) is used in Sanger DNA sequencing and in research related to viral infection[1][2][3][4][5].

2-5A (5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine) pentasodium is a 5'-triphosphorylated (2',5') oligoadenylate. 2-5A pentasodium is an immunotransmitter that fuels RNase L immunity. 2-5A pentasodium degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its endoribonuclease activity. 2-5A pentasodium can be used in RSV and cancer research.

2-5A is a 5'-triphosphorylated (2',5') oligoadenylate. 2-5A is an immunotransmitter that fuels RNase L immunity. 2-5A degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its endoribonuclease activity. 2-5A can be used in RSV and cancer research.

Adenosyl-(3′→5′)-uridine (ApU) sodium is a nucleotide, which is composed of an adenine base and a uracil sugar molecule through a 3'-5' phosphodiester bond. Adenosyl-(3′→5′)-uridine (ApU) sodium participates in the biological processes, such as gene expression regulation, signal transduction, and protein synthesis.

NAADP tetrasodium is a second messenger. NAADP tetrasodium releases Ca2+ from acidic endosomes and lysosomes. NAADP tetrasodium can be used to study cancer (such as oral squamous cell carcinoma, malignant melanoma) and angiogenesis-related diseases.

Parent CDN is a cyclic dinucleotide and a STING agonist. Parent CDN exhibits anti-tumor activity.

MDL 201112 is a carbocyclic nucleoside. MDL 201112 can decrease TNF-α production and inhibit MHC class II Ia+ antigen expression. MDL 201112 can be used for the research of inflammation and immunology.

dA-NHbenzylSCF 3 is a radiosensitizer. dA-NHbenzylSCF 3 has low toxicity to cancer cells and normal cells, but can significantly enhance cancer cell death in the presence of ionizing radiation (IR). dA-NHbenzylSCF 3 promotes cell apoptosis by capturing electrons and inducing DNA double strand breaks (DSBs). dA-NHbenzylSCF 3 is often used in the research of cancer, such as prostate cancer and breast cancer.

CFON-026 is a selective, orally active and non-covalent BTK inhibitor with an IC50 of 0.27  nM. CFON-026 has significant antitumor activity against wild-type BTK (TMD8 and REC-1) and all clinically relevant BTK resistance mutations (BTK C481S, T474I, L528W and V416L). CFON-026 induces complete tumor regression in TMD8 xenograft mice model. CFON-026 can be used for research of hematological cancers like chronic lymphocytic leukemia and waldenström macroglobulinemia.